Research Atlas · source screening

Bulevirtide

An attributable first-pass index of PubMed records whose titles name this governed identity. Records are sorted by publication date, not by evidence strength. Inclusion does not establish efficacy, safety, or a clinical indication.

Title-search results

122

Shown with stable PMIDs

24

Search recorded

2026-09-26

Source: NCBI PubMed / MEDLINE · exact query: "Bulevirtide"[Title] · up to 25 recent title matches per identity. Each result links to its PubMed record.

1. Beyond Virological Response: Refining the Assessment of Clinical and Patient-Reported Outcomes in Bulevirtide Therapy for Chronic Hepatitis D.

   J Viral Hepat · 2026 Oct · PMID 42764634 · DOI 10.1111/jvh.70233

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

2. Bulevirtide.

   Journal not recorded · 2006 · PMID 42766708

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

3. Modeling hepatitis D virus kinetics during bulevirtide monotherapy: challenges and solutions.

   J Theor Biol · 2026 Sep 14 · PMID 42735818 · DOI 10.1016/j.jtbi.2026.112595

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

4. Mathematical modeling of HDV RNA, HBsAg, and ALT kinetics in patients with compensated cirrhosis: Insights from 96 Weeks of bulevirtide monotherapy.

   Antiviral Res · 2026 Sep · PMID 42468832 · DOI 10.1016/j.antiviral.2026.106489

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

5. 144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial.

   J Hepatol · 2026 Sep · PMID 41966308 · DOI 10.1016/j.jhep.2026.03.046

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

6. Bulevirtide approved by FDA for chronic hepatitis D.

   Lancet Microbe · 2026 Aug 12 · PMID 42586109 · DOI 10.1016/j.lanmic.2026.101510

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

7. Bulevirtide (Hepcludex) for Chronic Hepatitis Delta: A Milestone Achievement Demanding Real-World Evaluation.

   Ann Pharmacother · 2026 Aug 9 · PMID 42571064 · DOI 10.1177/10600280261476305

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

8. Health Disparities in Hepatitis D Virus Management: A Case Series on Improving Patient Access to Bulevirtide Therapy.

   Gastro Hep Adv · 2026 · PMID 42740976 · DOI 10.1016/j.gastha.2026.101091

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

9. From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management.

   Liver Int · 2026 Aug · PMID 42358056 · DOI 10.1111/liv.70757

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

10. Fate of hepatitis D virus-specific CD8+ T cells during bulevirtide monotherapy in patients with chronic hepatitis delta.

    JHEP Rep · 2026 Jul 24 · PMID 42498134 · DOI 10.1016/j.jhepr.2026.101970

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

11. Pegylated interferon for chronic hepatitis delta: does it still have a role in the bulevirtide era?

    Rev Esp Enferm Dig · 2026 Jul 13 · PMID 42439394 · DOI 10.17235/reed.2026.12091/2026

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

12. HERACLIS_BLV_D: Adherence to Real-Life Therapy With Bulevirtide in Chronic Hepatitis D.

    J Viral Hepat · 2026 Jul · PMID 42322023 · DOI 10.1111/jvh.70201

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

13. Editorial: Bile Acids Under Bulevirtide-A Pharmacodynamic Signature, Not a Prognostic Biomarker. Authors' Reply.

    Aliment Pharmacol Ther · 2026 Jul · PMID 42186179 · DOI 10.1111/apt.70742

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

14. Editorial: Bile Acids Under Bulevirtide: A Pharmacodynamic Signature, Not a Prognostic Biomarker.

    Aliment Pharmacol Ther · 2026 Jul · PMID 42092232 · DOI 10.1111/apt.70707

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

15. Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D.

    Aliment Pharmacol Ther · 2026 Jul · PMID 42012135 · DOI 10.1111/apt.70675

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

16. Impact of sensitivity difference between two widely used HDV RNA quantification assays on the management of HDV-infected patients treated with bulevirtide.

    J Virol Methods · 2026 Jul · PMID 41935578 · DOI 10.1016/j.jviromet.2026.115394

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

17. Bulevirtide Acetate-gmod.

    Am J Health Syst Pharm · 2026 Jun 30 · PMID 42378446 · DOI 10.1093/ajhp/zxag193

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

18. Quantifying the delivered dose of bulevirtide in clinical trials and real-world use: A dose recovery study.

    J Hepatol · 2026 Jun 17 · PMID 42309286 · DOI 10.1016/j.jhep.2026.06.009

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

19. Modeling hepatitis D virus kinetics during bulevirtide monotherapy: challenges and solutions.

    ArXiv · 2026 Jun 4 · PMID 42282052

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

20. Bulevirtide for hepatitis D infection.

    Aust Prescr · 2026 Jun · PMID 42312304 · DOI 10.18773/austprescr.2026.020

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

21. Effectiveness, Safety and Patient-Reported Outcomes of Bulevirtide Therapy in Chronic Hepatitis Delta: Real-World Evidence From a Prospective Observational Study.

    J Viral Hepat · 2026 Jun · PMID 42108541 · DOI 10.1111/jvh.70181

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

22. HDV RNA Undetectability Rates During Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta May Be Assay Dependent.

    Liver Int · 2026 Jun · PMID 42104837 · DOI 10.1111/liv.70677

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

23. Response-guided bulevirtide ± pegylated interferon alfa-2a: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study.

    JHEP Rep · 2026 Jun · PMID 41903606 · DOI 10.1016/j.jhepr.2026.101835

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

24. Effects of bulevirtide on atherosclerosis in an ApoE-deficient mouse model.

    PLoS One · 2026 · PMID 42189807 · DOI 10.1371/journal.pone.0349211

    Source metadata only · evidence grade unassigned · scientific conclusions pending review